Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

被引：1

作者：

Johnson, Nathalie A. ^{[1
]}

Lavie, David ^{[2
]}

Borchmann, Peter ^{[3
]}

Gregory, Gareth P. ^{[4
]}

Herrera, Alex F. ^{[5
]}

Minuk, Leonard ^{[6
,7
]}

Vucinic, Vladan ^{[8
]}

Armand, Philippe ^{[9
]}

Avigdor, Abraham ^{[10
]}

Gasiorowski, Robin ^{[11
]}

Herishanu, Yair ^{[12
]}

Keane, Colm ^{[13
]}

Kuruvilla, John ^{[14
]}

Palcza, John ^{[15
]}

Pillai, Pallavi ^{[15
]}

Nahar, Akash ^{[15
]}

Timmerman, John ^{[16
]}

机构：

[1] Jewish Gen Hosp, Montreal, PQ, Canada

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Univ Klinikum Koeln AOER, Cologne, Germany

[4] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Vic, Australia

[5] City Hope Natl Med Ctr, Duarte, CA USA

[6] CancerCare Manitoba, Winnipeg, MB, Canada

[7] Univ Manitoba, Winnipeg, MB, Canada

[8] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Celltherapy & Hemostaseol, Leipzig, Germany

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Chaim Sheba Med Ctr, Ramat Gan, Israel

[11] Univ Sydney, Concord Hosp, Concord, Australia

[12] Sourasky Med Ctr, Tel Aviv, Israel

[13] Princess Alexandra Hosp, Brisbane, Qld, Australia

[14] Princess Margaret Canc Ctr, Toronto, ON, Canada

[15] Merck & Co Inc, Rahway, NJ 07065 USA

[16] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166846

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6540 / 6542

页数：3

共 50 条

[31] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
Deng, Lijuan
Li, Zhiming
Zhang, Huilai
Huang, Haiwen
Hu, Jianda
Liu, Lihong
Liu, Ting
Jin, Jie
Zhu, Zunmin
Li, Wenyu
Huang, Zhenqian
Huang, Wenrong
Zhou, Keshu
Yang, Haiyan
Zhang, Mingzhi
Ding, Kaiyang
Zhou, Hui
Hu, Yu
Shuang, Yuerong
Cao, Junning
Gao, Sujun
Li, Dengju
Sun, Zimin
Zhang, Qingyuan
Yi, Shuhua
Ji, Chunyan
Zhang, Liansheng
Hou, Cheng
Du, Yue
Wang, Weige
Zhao, Renbin
Song, Yuqin
Zhu, Jun
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750
[32] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Gopal, Ajay K.
Schuster, Stephen J.
Fowler, Nathan H.
Trotman, Judith
Hess, Georg
Hou, Jing-Zhou
Yacoub, Abdulraheem
Lill, Michael
Martin, Peter
Vitolo, Umberto
Spencer, Andrew
Radford, John
Jurczak, Wojciech
Morton, James
Caballero, Dolores
Deshpande, Sanjay
Gartenberg, Gary J.
Wang, Shean-Sheng
Damle, Rajendra N.
Schaffer, Michael
Balasubramanian, Sriram
Vermeulen, Jessica
Cheson, Bruce D.
Salles, Gilles
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2405 - +
[33] PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Witzig, T.
Sokol, L.
Jacobsen, E.
Advani, R.
Mondejar, R.
Piris, M.
Burrows, F.
Melvin, C.
Mishra, V.
Scholz, C.
Gualberto, A.
HAEMATOLOGICA, 2017, 102 : 222 - 222
[34] An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
Morschhauser, Franck
Salles, Gilles
Le Gouill, Steven
Tilly, Herve
Thieblemont, Catherine
Bouabdallah, Krimo
Fabiani, Bettina
Menard, Cedric
Tarte, Karin
Cartron, Guillaume
Houot, Roch
BLOOD, 2018, 132 (14) : 1486 - 1494
[35] Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Coyle, Luke
Morley, Nicholas J.
Rambaldi, Alessandro
Mason, Kylie D.
Verhoef, Gregor
Furness, Caroline
Desai, Rajendra
Mergen, Noemi
BLOOD, 2020, 136
[36] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study
Zinzani, P. L.
Kline, J.
Chen, R.
Ribrag, V.
Salles, G.
Matsumura, I.
Zhu, Y.
Ricart, A.
Balakumaran, A.
Fanale, M.
ANNALS OF ONCOLOGY, 2016, 27
[37] PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RANDOMIZED, PHASE 3 KEYNOTE-204 STUDY
Fanale, M. A.
Kline, J.
Chen, R.
Ribrag, V.
Salles, G.
Matsumura, I.
Zhu, Y.
Ricart, A. D.
Balakumaran, A.
Zinzani, P. L.
HAEMATOLOGICA, 2016, 101 : 60 - 60
[38] AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
Sasse, Stephanie
Momotow, Jesko
Plutschow, Annette
Huttmann, Andreas
Basara, Nadezda
Koenecke, Christian
Martin, Sonja
Bentz, Martin
Grosse-Thie, Christina
Thorspecken, Sven
de Wit, Maike
Kobe, Carsten
Dietlein, Markus
von Tresckow, Bastian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
BLOOD, 2020, 136
[39] AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial
Momotow, J.
Sasse, S.
Pluetschow, A.
Huettmann, A.
Basara, N.
Koenecke, C.
Martin, S.
Bentz, M.
Grosse-Thie, C.
Thorspecken, S.
de Wit, M.
Kobe, C.
Dietlein, M.
von Tresckow, B.
Fuchs, M.
Borchmann, P.
Engert, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 89 - 89
[40] Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study
Yusuf, Rushdia
Jemielita, Thomas
Marinello, Patricia
BLOOD, 2021, 138

← 1 2 3 4 5 →